Mexib 6, 125 mg+10 mg 30 pcs

Cardialgia (heart pain), Atherosclerosis, Neurosis, Dizziness, Vascular disorders, Asthenia, Impaired cerebral circulation, Exposure to adverse factors

In the combined therapy:

• discirculatory encephalopathy;
• syndrome of autonomic dystonia;
• anxiety in neurotic and neurosis-like states;
• abstinence syndrome in alcoholism with predominance of neurosis-like and vegetative-vascular disorders;
• Absicion syndrome in alcoholismischemic heart disease (prevention of attacks);
• states after acute intoxication with antipsychotic drugs
• sthenic conditions, and to prevent the development of somatic diseases under the influence of extreme factors and loads
• exposure to extreme (stress) factors.

.

Indications

As part of combination therapy:

dyscirculatory encephalopathy;
vegetative dystonia syndrome;
anxiety states in neurotic and neurosis-like conditions;
withdrawal syndrome in alcoholism with a predominance of neurological and vegetative-vascular disorders;
coronary heart disease (prevention of attacks);
conditions after acute intoxication with antipsychotic drugs;
asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and stress;
influence of extreme (stressful) factors.

Pharmacological effect

MexiV 6® is a combination drug.

Special instructions

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Ethylmethylhydroxypyridine succinate, Pyridoxine

Composition

Dosage form:

film-coated tablets

Composition:

1 film-coated tablet contains:

Active substances:

ethylmethylhydroxypyridine succinate 125 mg,

pyridoxine hydrochloride 10 mg;

Excipients:

calcium hydrogen phosphate dihydrate, copovidone (Kollidon VA-64 or Plasdon Es-630),

colloidal silicon dioxide (aerosil),

croscarmellose sodium (primellose),

magnesium lactate, magnesium stearate,

hydrogenated castor oil,

microcrystalline cellulose;

Film shell composition:

Selecote AQ-02003 [hypromellose (hydroxypropyl methylcellulose), macrogol (polyethylene glycol 6000), titanium dioxide].

Contraindications

Hypersensitivity; acute liver and/or kidney failure; pregnancy, lactation, childhood.

With caution

Peptic ulcer of the stomach and duodenum.

Side Effects

Nausea, dry mouth, diarrhea, drowsiness, allergic reactions, hypersecretion of hydrochloric acid (HCl), numbness, a feeling of constriction in the limbs – a symptom of “stockings” and “gloves”, decreased lactation (sometimes this is used as a therapeutic effect).

Interaction

Enhances the effect of benzodiazepine anxiolytics, antiepileptics (carbamazepine), antiparkinsonian drugs (levodopa), nitrates.

Reduces the toxic effects of ethanol.

Strengthens the effect of diuretics; combines well with cardiac glycosides (pyridoxine helps increase the synthesis of contractile proteins in the myocardium), with glutamic acid and potassium and magnesium aspartate (increases resistance to hypoxia).

Pyridoxine is pharmaceutically incompatible with thiamine and cyanocobalamin. Isoniazid, penicillamine, cycloserine and estrogen-containing oral contraceptives weaken the effect of pyridoxine.

Overdose

Symptoms: sleep disturbances (insomnia, in some cases drowsiness).

Treatment, as a rule, is not required – the symptoms disappear on their own within 24 hours. In severe cases of insomnia – nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.

Manufacturer

Kanonpharma production CJSC, Russia